Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Chinese Journal of Interventional Cardiology ; (4): 87-92, 2018.
Article in Chinese | WPRIM | ID: wpr-702319

ABSTRACT

Objective To investigate the clinical features of patients with acute ST-segment elevation myocardial infarction (STEMI) comorbid with diabetes mellitus (DM) and to analyze the prognosis within 12 months after primary percutaneous coronary intervention (pre-PCI). Methods A total of 375 STEMI patients were divided into the diabetes group (n=140) and the normal blood glucose group(n=235) according to whether they met the diagnostic criteria of DH. The clinical data,characteristics of coronary artery lesions,type of stent implant,rate of coronary slow flow or no-reflow after pre-PCI, and the prognosis within 12 months after PCI of the two groups were investigated.Results Patient in the diabetes group presented with higher mean age ,higher comorbid rates of hypertension , hyperlipidemia and heart function of Killip class Ш and above than patients in the normal blood glucose group (all P<0.05). patients in the diabetes group had higher rates of slow reflow /no-reflow after PCI(12.9% vs.5.5%,P=0.013),higher percentages of 3-ressel disease(40.7% vs. 28.9%,P=0.019)and lef t main lesions(13.6% vs. 7.2%,P=0.044). The in-hospital mortality rates(6.4% vs.1.7%,P=0.020),revascularization rates within 12 months(7.9% vs.0.9%,P=0.001)and incidence of heart failure(7.9% vs. 2.6%,P=0.017)were all higher in the diabetes group. Conclusions STEMI patients comorbid with DM were relatively older, had higher comorbidities of hypertension,hyperlipidemia, three-vessel disease, left main coronary lesions and higher mortality during hospitalization. No significant increase in cardiac death and recurrent myocardial infarction were deserved during the follow-up period. These patients may benefit more from early intervention.

2.
National Journal of Andrology ; (12): 1138-1141, 2009.
Article in Chinese | WPRIM | ID: wpr-252850

ABSTRACT

<p><b>OBJECTIVE</b>To observe the clinical efficacy of Shenfu Qiangjing Decoction (SQD) in the treatment of non-inflammatory and non-liquefied semen in infertile males with kidney-yang deficiency.</p><p><b>METHODS</b>Sixty cases of male infertility caused by non-inflammatory and non-liquefied semen with kidney-yang deficiency were equally and randomly divided into an SQD and a control group, the former given oral SQD and the latter vitamin C tablets plus intramuscular chymotrypsin. Both groups were observed for sperm viability, sperm motility, serum testosterone, seminal plasma PSA and improvement of kidney-yang deficiency symptoms before and after the medication. The therapeutic effects were evaluated according to the semen liquefaction within 60 min.</p><p><b>RESULTS</b>Statistically significant differences were observed in the improvement of kidney-yang deficiency symptoms after the medication between the SQD and control groups (P < 0.01, P < 0.05) , and in sperm viability and motility of the SQD group before and after the treatment (P < 0.01) as well as between the two groups after the medication (P < 0.05). The levels of serum T and seminal plasma PSA also showed significant differences before and after the treatment in the SQD group (P < 0.01) and between the two groups after the medication (P < 0.05). The rate of total effectiveness was 93.3% in the SQD and 76.7% in the control group (P < 0.05).</p><p><b>CONCLUSION</b>SQD can shorten the semen liquefaction time in patients with non-inflammatory and non-liquefied semen and restore semen liquefaction to normal in over 90% of the patients. Meanwhile it can also improve the low testosterone level resulting from various kidney-yang deficiency symptoms.</p>


Subject(s)
Adult , Humans , Male , Young Adult , Drugs, Chinese Herbal , Therapeutic Uses , Infertility, Male , Drug Therapy , Phytotherapy , Semen Analysis , Sperm Motility , Yang Deficiency , Drug Therapy
SELECTION OF CITATIONS
SEARCH DETAIL